Treatment resistance to platinum-based chemotherapy in lung and ovarian cancer is driven by a targetable TGFβ senescent secretome.
González-Gualda E, Reinius MAV, Macias D, Morsli S, Ge J, Olan I, Martín JE, Ou HL, Hartono M, Puerto-Camacho MP, Denholm M, Kieran R, Hoffmann R, Dane M, Veroutis D, Medrano G, Mulero F, Jimenez-Linan M, Fruk L, Martins CP, Barbacid M, Gorgoulis V, Korkola JE, Rassl DM, Doherty GJ, Rintoul RC, Narita M, Brenton JD, Muñoz-Espín D.
González-Gualda E, et al. Among authors: munoz espin d.
Nat Aging. 2026 Feb;6(2):368-392. doi: 10.1038/s43587-025-01054-2. Epub 2026 Feb 3.
Nat Aging. 2026.
PMID: 41634464
Free PMC article.
Platinum-based chemotherapy is commonly used for non-small cell lung cancer (NSCLC) and high-grade serous ovarian cancer (HGSOC) treatments, yet clinical outcomes remain poor. Cellular senescence and its associated secretory phenotype (SASP) can have multiple …
Platinum-based chemotherapy is commonly used for non-small cell lung cancer (NSCLC) and high-grade serous ovarian cancer (HGSOC) trea …